Global (United States, European Union and China) Tecentriq research
Global (United States, European Union and China) Tecentriq research

Tecentriq Comprehensive Study by Application (Lung Problems, Intestinal Problems, Liver Problems, Hormone Gland Problems, Kidney Problems, Skin Problems, Others), End User (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2026

Tecentriq Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 241 Pages 169 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Tecentriq Market Overview:
Tecentriq is a kind of prescription neoplastic agent used in the treatment of gall bladder cancer, urinary tract cancer, some kind of lung as well as breast cancer. The technique is used when cancer has spread to other parts of the body or can't be removed by surgery. Tecentriq is also used when there is a problem in giving cisplatin-containing chemotherapy.

Growth Drivers
  • Increasing Incidences of Bladder, Lung, Breast Cancers Globally
  • Rising R&D Investments by Pharmaceutical Industries to Study New Candidate

Market Trends
  • Increasing Use of Tecentriq for Treatment of the Cancer

Roadblocks
  • High Cost of Treatment

Opportunities
  • Technological Advancement and Development in the Tecentriq By Various Manufacturers

Challenges
  • Various Side Effect of the Drug


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Genentech, Inc. (United States), Roche (Switzerland), Thermo Fisher Scientific (United States), Siemens Healthcare GmbH (Germany), Merck & Company, Inc. (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States), Bio-Rad Technologies Inc. (United States), Abbott (United States), GlaxoSmithKline plc (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland) and Becton, Dickinson, and Company (United States). Considering Market by End User, the sub-segment i.e. Hospital will boost the Tecentriq market.

Recently, Roche has won approval from the FDA for its immunotherapy Tecentriq in certain patients with first-line non-small cell lung cancer (NSCLC), a market which is largely dominated by Merck/MSD’s rival Keytruda.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Tecentriq market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Tecentriq market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Tecentriq Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Application
  • Lung Problems
  • Intestinal Problems
  • Liver Problems
  • Hormone Gland Problems
  • Kidney Problems
  • Skin Problems
  • Others
By End User
  • Hospital
  • Clinic
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Bladder, Lung, Breast Cancers Globally
      • 3.2.2. Rising R&D Investments by Pharmaceutical Industries to Study New Candidate
    • 3.3. Market Challenges
      • 3.3.1. Various Side Effect of the Drug
    • 3.4. Market Trends
      • 3.4.1. Increasing Use of Tecentriq for Treatment of the Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tecentriq, by Application, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Tecentriq (Value)
      • 5.2.1. Global Tecentriq by: Application (Value)
        • 5.2.1.1. Lung Problems
        • 5.2.1.2. Intestinal Problems
        • 5.2.1.3. Liver Problems
        • 5.2.1.4. Hormone Gland Problems
        • 5.2.1.5. Kidney Problems
        • 5.2.1.6. Skin Problems
        • 5.2.1.7. Others
      • 5.2.2. Global Tecentriq by: End User (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Tecentriq Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Tecentriq: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genentech, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Siemens Healthcare GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Company, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio-Rad Technologies Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Becton, Dickinson, and Company (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Tecentriq Sale, by Application, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Tecentriq (Value)
      • 7.2.1. Global Tecentriq by: Application (Value)
        • 7.2.1.1. Lung Problems
        • 7.2.1.2. Intestinal Problems
        • 7.2.1.3. Liver Problems
        • 7.2.1.4. Hormone Gland Problems
        • 7.2.1.5. Kidney Problems
        • 7.2.1.6. Skin Problems
        • 7.2.1.7. Others
      • 7.2.2. Global Tecentriq by: End User (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Tecentriq Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tecentriq: by Application(USD Million)
  • Table 2. Tecentriq Lung Problems , by Region USD Million (2015-2020)
  • Table 3. Tecentriq Intestinal Problems , by Region USD Million (2015-2020)
  • Table 4. Tecentriq Liver Problems , by Region USD Million (2015-2020)
  • Table 5. Tecentriq Hormone Gland Problems , by Region USD Million (2015-2020)
  • Table 6. Tecentriq Kidney Problems , by Region USD Million (2015-2020)
  • Table 7. Tecentriq Skin Problems , by Region USD Million (2015-2020)
  • Table 8. Tecentriq Others , by Region USD Million (2015-2020)
  • Table 9. Tecentriq: by End User(USD Million)
  • Table 10. Tecentriq Hospital , by Region USD Million (2015-2020)
  • Table 11. Tecentriq Clinic , by Region USD Million (2015-2020)
  • Table 12. Tecentriq Others , by Region USD Million (2015-2020)
  • Table 13. South America Tecentriq, by Country USD Million (2015-2020)
  • Table 14. South America Tecentriq, by Application USD Million (2015-2020)
  • Table 15. South America Tecentriq, by End User USD Million (2015-2020)
  • Table 16. Brazil Tecentriq, by Application USD Million (2015-2020)
  • Table 17. Brazil Tecentriq, by End User USD Million (2015-2020)
  • Table 18. Argentina Tecentriq, by Application USD Million (2015-2020)
  • Table 19. Argentina Tecentriq, by End User USD Million (2015-2020)
  • Table 20. Rest of South America Tecentriq, by Application USD Million (2015-2020)
  • Table 21. Rest of South America Tecentriq, by End User USD Million (2015-2020)
  • Table 22. Asia Pacific Tecentriq, by Country USD Million (2015-2020)
  • Table 23. Asia Pacific Tecentriq, by Application USD Million (2015-2020)
  • Table 24. Asia Pacific Tecentriq, by End User USD Million (2015-2020)
  • Table 25. China Tecentriq, by Application USD Million (2015-2020)
  • Table 26. China Tecentriq, by End User USD Million (2015-2020)
  • Table 27. Japan Tecentriq, by Application USD Million (2015-2020)
  • Table 28. Japan Tecentriq, by End User USD Million (2015-2020)
  • Table 29. India Tecentriq, by Application USD Million (2015-2020)
  • Table 30. India Tecentriq, by End User USD Million (2015-2020)
  • Table 31. South Korea Tecentriq, by Application USD Million (2015-2020)
  • Table 32. South Korea Tecentriq, by End User USD Million (2015-2020)
  • Table 33. Taiwan Tecentriq, by Application USD Million (2015-2020)
  • Table 34. Taiwan Tecentriq, by End User USD Million (2015-2020)
  • Table 35. Australia Tecentriq, by Application USD Million (2015-2020)
  • Table 36. Australia Tecentriq, by End User USD Million (2015-2020)
  • Table 37. Rest of Asia-Pacific Tecentriq, by Application USD Million (2015-2020)
  • Table 38. Rest of Asia-Pacific Tecentriq, by End User USD Million (2015-2020)
  • Table 39. Europe Tecentriq, by Country USD Million (2015-2020)
  • Table 40. Europe Tecentriq, by Application USD Million (2015-2020)
  • Table 41. Europe Tecentriq, by End User USD Million (2015-2020)
  • Table 42. Germany Tecentriq, by Application USD Million (2015-2020)
  • Table 43. Germany Tecentriq, by End User USD Million (2015-2020)
  • Table 44. France Tecentriq, by Application USD Million (2015-2020)
  • Table 45. France Tecentriq, by End User USD Million (2015-2020)
  • Table 46. Italy Tecentriq, by Application USD Million (2015-2020)
  • Table 47. Italy Tecentriq, by End User USD Million (2015-2020)
  • Table 48. United Kingdom Tecentriq, by Application USD Million (2015-2020)
  • Table 49. United Kingdom Tecentriq, by End User USD Million (2015-2020)
  • Table 50. Netherlands Tecentriq, by Application USD Million (2015-2020)
  • Table 51. Netherlands Tecentriq, by End User USD Million (2015-2020)
  • Table 52. Rest of Europe Tecentriq, by Application USD Million (2015-2020)
  • Table 53. Rest of Europe Tecentriq, by End User USD Million (2015-2020)
  • Table 54. MEA Tecentriq, by Country USD Million (2015-2020)
  • Table 55. MEA Tecentriq, by Application USD Million (2015-2020)
  • Table 56. MEA Tecentriq, by End User USD Million (2015-2020)
  • Table 57. Middle East Tecentriq, by Application USD Million (2015-2020)
  • Table 58. Middle East Tecentriq, by End User USD Million (2015-2020)
  • Table 59. Africa Tecentriq, by Application USD Million (2015-2020)
  • Table 60. Africa Tecentriq, by End User USD Million (2015-2020)
  • Table 61. North America Tecentriq, by Country USD Million (2015-2020)
  • Table 62. North America Tecentriq, by Application USD Million (2015-2020)
  • Table 63. North America Tecentriq, by End User USD Million (2015-2020)
  • Table 64. United States Tecentriq, by Application USD Million (2015-2020)
  • Table 65. United States Tecentriq, by End User USD Million (2015-2020)
  • Table 66. Canada Tecentriq, by Application USD Million (2015-2020)
  • Table 67. Canada Tecentriq, by End User USD Million (2015-2020)
  • Table 68. Mexico Tecentriq, by Application USD Million (2015-2020)
  • Table 69. Mexico Tecentriq, by End User USD Million (2015-2020)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Tecentriq: by Application(USD Million)
  • Table 83. Tecentriq Lung Problems , by Region USD Million (2021-2026)
  • Table 84. Tecentriq Intestinal Problems , by Region USD Million (2021-2026)
  • Table 85. Tecentriq Liver Problems , by Region USD Million (2021-2026)
  • Table 86. Tecentriq Hormone Gland Problems , by Region USD Million (2021-2026)
  • Table 87. Tecentriq Kidney Problems , by Region USD Million (2021-2026)
  • Table 88. Tecentriq Skin Problems , by Region USD Million (2021-2026)
  • Table 89. Tecentriq Others , by Region USD Million (2021-2026)
  • Table 90. Tecentriq: by End User(USD Million)
  • Table 91. Tecentriq Hospital , by Region USD Million (2021-2026)
  • Table 92. Tecentriq Clinic , by Region USD Million (2021-2026)
  • Table 93. Tecentriq Others , by Region USD Million (2021-2026)
  • Table 94. South America Tecentriq, by Country USD Million (2021-2026)
  • Table 95. South America Tecentriq, by Application USD Million (2021-2026)
  • Table 96. South America Tecentriq, by End User USD Million (2021-2026)
  • Table 97. Brazil Tecentriq, by Application USD Million (2021-2026)
  • Table 98. Brazil Tecentriq, by End User USD Million (2021-2026)
  • Table 99. Argentina Tecentriq, by Application USD Million (2021-2026)
  • Table 100. Argentina Tecentriq, by End User USD Million (2021-2026)
  • Table 101. Rest of South America Tecentriq, by Application USD Million (2021-2026)
  • Table 102. Rest of South America Tecentriq, by End User USD Million (2021-2026)
  • Table 103. Asia Pacific Tecentriq, by Country USD Million (2021-2026)
  • Table 104. Asia Pacific Tecentriq, by Application USD Million (2021-2026)
  • Table 105. Asia Pacific Tecentriq, by End User USD Million (2021-2026)
  • Table 106. China Tecentriq, by Application USD Million (2021-2026)
  • Table 107. China Tecentriq, by End User USD Million (2021-2026)
  • Table 108. Japan Tecentriq, by Application USD Million (2021-2026)
  • Table 109. Japan Tecentriq, by End User USD Million (2021-2026)
  • Table 110. India Tecentriq, by Application USD Million (2021-2026)
  • Table 111. India Tecentriq, by End User USD Million (2021-2026)
  • Table 112. South Korea Tecentriq, by Application USD Million (2021-2026)
  • Table 113. South Korea Tecentriq, by End User USD Million (2021-2026)
  • Table 114. Taiwan Tecentriq, by Application USD Million (2021-2026)
  • Table 115. Taiwan Tecentriq, by End User USD Million (2021-2026)
  • Table 116. Australia Tecentriq, by Application USD Million (2021-2026)
  • Table 117. Australia Tecentriq, by End User USD Million (2021-2026)
  • Table 118. Rest of Asia-Pacific Tecentriq, by Application USD Million (2021-2026)
  • Table 119. Rest of Asia-Pacific Tecentriq, by End User USD Million (2021-2026)
  • Table 120. Europe Tecentriq, by Country USD Million (2021-2026)
  • Table 121. Europe Tecentriq, by Application USD Million (2021-2026)
  • Table 122. Europe Tecentriq, by End User USD Million (2021-2026)
  • Table 123. Germany Tecentriq, by Application USD Million (2021-2026)
  • Table 124. Germany Tecentriq, by End User USD Million (2021-2026)
  • Table 125. France Tecentriq, by Application USD Million (2021-2026)
  • Table 126. France Tecentriq, by End User USD Million (2021-2026)
  • Table 127. Italy Tecentriq, by Application USD Million (2021-2026)
  • Table 128. Italy Tecentriq, by End User USD Million (2021-2026)
  • Table 129. United Kingdom Tecentriq, by Application USD Million (2021-2026)
  • Table 130. United Kingdom Tecentriq, by End User USD Million (2021-2026)
  • Table 131. Netherlands Tecentriq, by Application USD Million (2021-2026)
  • Table 132. Netherlands Tecentriq, by End User USD Million (2021-2026)
  • Table 133. Rest of Europe Tecentriq, by Application USD Million (2021-2026)
  • Table 134. Rest of Europe Tecentriq, by End User USD Million (2021-2026)
  • Table 135. MEA Tecentriq, by Country USD Million (2021-2026)
  • Table 136. MEA Tecentriq, by Application USD Million (2021-2026)
  • Table 137. MEA Tecentriq, by End User USD Million (2021-2026)
  • Table 138. Middle East Tecentriq, by Application USD Million (2021-2026)
  • Table 139. Middle East Tecentriq, by End User USD Million (2021-2026)
  • Table 140. Africa Tecentriq, by Application USD Million (2021-2026)
  • Table 141. Africa Tecentriq, by End User USD Million (2021-2026)
  • Table 142. North America Tecentriq, by Country USD Million (2021-2026)
  • Table 143. North America Tecentriq, by Application USD Million (2021-2026)
  • Table 144. North America Tecentriq, by End User USD Million (2021-2026)
  • Table 145. United States Tecentriq, by Application USD Million (2021-2026)
  • Table 146. United States Tecentriq, by End User USD Million (2021-2026)
  • Table 147. Canada Tecentriq, by Application USD Million (2021-2026)
  • Table 148. Canada Tecentriq, by End User USD Million (2021-2026)
  • Table 149. Mexico Tecentriq, by Application USD Million (2021-2026)
  • Table 150. Mexico Tecentriq, by End User USD Million (2021-2026)
  • Table 151. Research Programs/Design for This Report
  • Table 152. Key Data Information from Secondary Sources
  • Table 153. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tecentriq: by Application USD Million (2015-2020)
  • Figure 5. Global Tecentriq: by End User USD Million (2015-2020)
  • Figure 6. South America Tecentriq Share (%), by Country
  • Figure 7. Asia Pacific Tecentriq Share (%), by Country
  • Figure 8. Europe Tecentriq Share (%), by Country
  • Figure 9. MEA Tecentriq Share (%), by Country
  • Figure 10. North America Tecentriq Share (%), by Country
  • Figure 11. Global Tecentriq share by Players 2020 (%)
  • Figure 12. Global Tecentriq share by Players (Top 3) 2020(%)
  • Figure 13. Global Tecentriq share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Genentech, Inc. (United States) Revenue: by Geography 2020
  • Figure 17. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche (Switzerland) Revenue: by Geography 2020
  • Figure 19. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 20. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 21. Siemens Healthcare GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Siemens Healthcare GmbH (Germany) Revenue: by Geography 2020
  • Figure 23. Merck & Company, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Company, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Bio-Rad Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bio-Rad Technologies Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 32. Abbott (United States) Revenue: by Geography 2020
  • Figure 33. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 35. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 37. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Becton, Dickinson, and Company (United States) Revenue: by Geography 2020
  • Figure 39. Global Tecentriq: by Application USD Million (2021-2026)
  • Figure 40. Global Tecentriq: by End User USD Million (2021-2026)
  • Figure 41. South America Tecentriq Share (%), by Country
  • Figure 42. Asia Pacific Tecentriq Share (%), by Country
  • Figure 43. Europe Tecentriq Share (%), by Country
  • Figure 44. MEA Tecentriq Share (%), by Country
  • Figure 45. North America Tecentriq Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Genentech, Inc. (United States)
  • Roche (Switzerland)
  • Thermo Fisher Scientific (United States)
  • Siemens Healthcare GmbH (Germany)
  • Merck & Company, Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
  • Bio-Rad Technologies Inc. (United States)
  • Abbott (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Becton, Dickinson, and Company (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation